NCT06667622 Sodium Glycididazole Reduces the Adverse Reactions of Concurrent Chemoradiotherapy
| NCT ID | NCT06667622 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
| Condition | Chemoradiotherapy |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2024-05-29 |
| Primary Completion | 2026-01-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 40 participants in total. It began in 2024-05-29 with a primary completion date of 2026-01-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To evaluate the efficacy and toxicity of sodium glycididazole combined with concurrent chemoradiotherapy in patients with unresectable locally advanced non-small cell lung cancer after neoadjuvant chemoradiotherapy.
Eligibility Criteria
Inclusion Criteria: 1. Patients must have histologically or cytologically confirmed non-small cell lung cancer. 2. Patients with unresectable stage II-III non-small cell lung cancer after neoadjuvant therapy. 3. ECOG PS 0-2 4. Adequate organ and bone marrow function. Exclusion Criteria: 1. History of previous radiotherapy. 2. The previous immune-related pneumonitis ≥ grade 2. 3. Local lesions require surgery. 4. History of another primary malignancy. 5. History of active primary immunodeficiency. 6. Histological findings showed mixed small cell lung cancer and non-small cell lung cancer. 7. For any unmitigated toxicity during pre-study chemoradiotherapy.
Contact & Investigator
Lei Deng, MD
STUDY CHAIR
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Frequently Asked Questions
Who can join the NCT06667622 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Chemoradiotherapy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06667622 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06667622 currently recruiting?
Yes, NCT06667622 is actively recruiting participants. Contact the research team at dengleipumc@163.com for enrollment information.
Where is the NCT06667622 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06667622 clinical trial?
NCT06667622 is sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. The principal investigator is Lei Deng, MD at Cancer Institute and Hospital, Chinese Academy of Medical Sciences. The trial plans to enroll 40 participants.